Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hoth Therapeutics Acquires New Patent Applications | Contract Pharma

What are you searching for?

Sign in
Breaking News

Hoth Therapeutics Acquires New Patent Applications

Enhances its intellectual property portfolio.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Hoth Therapeutics Inc., a patient-focused biopharmaceutical company, has enhanced its intellectual property portfolio by acquiring and expanding patent applications to its therapeutic pipeline.

These newly secured patents reflect Hoth’s commitment to pioneering treatments that address unmet medical needs, with a focus on enhancing therapeutic efficacy and broadening applications across various disease areas.

“Our expanding intellectual property portfolio supports Hoth’s position as a leader in innovative drug development,” said Robb Knie, CEO of Hoth Therapeutics. “These provisional patent applications reinforce our proprietary approaches and our mission to deliver breakthrough therapies that improve patients’ lives.”

Hoth Therapeutics continues to invest in research and development strategies, ensuring the protection and growth of its proprietary technologies. The company remains dedicated to advancing its pipeline and delivering impactful healthcare solutions.

More Hoth Therapeutics News

In August, Hoth Therapeutics entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics